CClinicalTrials.gg
Sign In
Status unknownNCT05317039Updated Apr 7, 2022

Piezosurgical Buccal Plate Repositioning Technique for Horizontal Alveolar Ridge Augmentation

An interventional study of silica-calcium phosphate nanocomposite SCPC and freezed dried bone in Alveolar Bone Loss, sponsored by Hams Hamed Abdelrahman. Status unknown at 1 site in Egypt. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-04-07.

Sponsored by Hams Hamed Abdelrahman · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2021, registered Mar 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

Achieving prosthetically driven implant placement is a highly predictable treatment modality with reliable long-term results. Different surgical procedures have been used as a solution for reconstructing of the alveolar ridge with deficient volume. In the present study we demonstrate a modified alveolar ridge split technique for horizontal alveolar ridge augmentation (buccal plate repositioning technique) using the piezotome surgery. Evaluation of the effect of silica-calcium phosphate nanocomposite (SCPC) graft material versus demineralized freeze dried bone allograft (DFBA) in horizontal alveolar ridge augmentation before implant insertion will be performed.

02

Conditions studied

  • Alveolar Bone Loss

Browse trials for

03

In context

Alveolar Bone Loss

297 studies on the registry are indexed under Alveolar Bone Loss; 76 are open to participants now.

This study's planned enrollment of 18 is below the median of 25 across 254 interventional studies indexed under Alveolar Bone Loss.

Browse Alveolar Bone Loss studies →

Lead sponsor

Hams Hamed Abdelrahman is the lead sponsor of 107 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with horizontal atrophy of the posterior mandible with pristine residual alveolar crest width from 2 to 4 mm.
  • Augmented area length in the mesial-distal direction of less than 20 mm.
  • Adequate physically healthy condition.

Exclusion criteria

Exclusion Criteria:

  • A systemic disease that would contraindicate oral surgical treatment.
  • Treated patients who had undergone therapy involving radiation
  • Patients who had received bone resection as part of an oncological treatment after a bone augmentation procedure.
  • Patients are subjected to intravenous and/or oral bisphosphonate therapy after the bone augmentation procedure.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Group A

    Group A will be treated with the buccal plate repositioning technique and grafted with SCPC.

    Other: silica-calcium phosphate nanocomposite SCPC

  • Active comparator
    Group B

    Group B will be similarly managed and grafted using DFDBA

    Other: freezed dried bone

Interventions

  • Othersilica-calcium phosphate nanocomposite SCPC

    Patients will be treated with the buccal plate repositioning technique and grafted with SCPC then the grafted defect will be covered with a platelet-rich fibrin membrane.

  • Otherfreezed dried bone

    Patients will be treated with the buccal plate repositioning technique and grafted using DFDBA. then the grafted defect will be covered with a platelet-rich fibrin membrane.

06

What researchers measure

Primary outcomes

  1. change in alveolar ridge width

    All patients will receive a CBCT scan; immediately after surgery and at 6 months post-operatively. The images will be analyzed using OnDemand3D software (Cybermed Inc) CBCT analyzing software and compared to the pre-operative scan for alveolar ridge width evaluation.

    Time frame: at baseline and 6 months

07

Study locations

1 site
  • Alexandria Faculty of Dentistry
    Alexandria, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05317039
Lead sponsor
Hams Hamed Abdelrahman
Responsible party
Hams Hamed Abdelrahman (Assistant lecturer of DPH and Clinical statistician, Alexandria University) — Sponsor-investigator
First posted
Apr 7, 2022
Start date
Aug 15, 2021
Primary completion
Jun 30, 2022 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Apr 7, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Alveolar Bone Loss→

Other studies from this sponsor

Hams Hamed Abdelrahman

Start the discussion